Martine Rothblatt Net Worth

The estimated Net Worth of Martine A Rothblatt is at least $56.6 Milion dollars as of 26 August 2024. Martine Rothblatt owns over 269 units of United Therapeutics Corp stock worth over $138,130 and over the last 20 years he sold UTHR stock worth over $40,880,017. In addition, he makes $15,627,500 as Chairman of the Board i Chief Executive Officer at United Therapeutics Corp.

Martine Rothblatt UTHR stock SEC Form 4 insiders trading

Martine has made over 864 trades of the United Therapeutics Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 269 units of UTHR stock worth $34,833 on 26 August 2024.

The largest trade he's ever made was exercising 50,000 units of United Therapeutics Corp stock on 15 September 2014 worth over $2,632,000. On average, Martine trades about 7,994 units every 8 days since 2004. As of 26 August 2024 he still owns at least 399 units of United Therapeutics Corp stock.

You can see the complete history of Martine Rothblatt stock trades at the bottom of the page.

Martine Rothblatt biography

Dr. Martine A. Rothblatt Ph.D. J.D. serves as Chairman of the Board, Chief Executive Officer of the Company. She became our Chairman and Co-Chief Executive Officer. She was promoted to her current role as Chairman and soul CEO in June 2016. Prior to founding United Therapeutics, she founded and served as Chairman and Chief Executive Officer of Sirius XM Satellite Radio. She is a co-inventor on six of our patents pertaining to treprostinil. In 2014, Dr. Rothblatt was appointed to the Committee of Science, Technology and Law of the National Research Council. She has served as a United Therapeutics director since 1996. Dr. Rothblatt brings to our Board extensive leadership and business experience at technology companies, as well as in-depth knowledge of our company from her service as our founder, Chairman and Chief Executive Officer. She also has substantial knowledge of medical ethics, having obtained her Ph.D. in medical ethics from the University of London.

What is the salary of Martine Rothblatt?

As the Chairman of the Board i Chief Executive Officer of United Therapeutics Corp, the total compensation of Martine Rothblatt at United Therapeutics Corp is $15,627,500. There are no executives at United Therapeutics Corp getting paid more.

How old is Martine Rothblatt?

Martine Rothblatt is 65, he's been the Chairman of the Board i Chief Executive Officer of United Therapeutics Corp since 2016. There are 7 older and 13 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.

What's Martine Rothblatt's mailing address?

Martine's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.

Insiders trading at United Therapeutics Corp

Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli oraz Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.

What does United Therapeutics Corp do?

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Complete history of Martine Rothblatt stock trades at United Therapeutics Corp